Akari Therapeutics Plc 8-K

What Happened
Akari Therapeutics Plc announced on March 17, 2026 (Form 8-K filed same day) that it will change the ratio of its American Depositary Shares (ADSs) from 1 ADS = 2,000 Ordinary Shares to 1 ADS = 80,000 Ordinary Shares. The Ratio Change constitutes a one-for-forty reverse split of issued and outstanding ADSs and is expected to be effective on or about March 31, 2026. The Company issued a press release on March 17, 2026 to disclose the change.

Key Details

• Ratio Change: one-for-forty reverse split of ADSs (old: 1 ADS = 2,000 Ordinary Shares; new: 1 ADS = 80,000 Ordinary Shares).
• Effective date: on or about March 31, 2026.
• Ordinary Shares: the reverse split affects ADSs only and will have no effect on the underlying Ordinary Shares.
• Nasdaq note: the market price per ADS is expected to increase proportionally, but the Company cannot assure the split will enable it to meet or maintain Nasdaq’s minimum bid price requirement.

Why It Matters
A reverse split reduces the number of ADSs outstanding and typically raises the per-ADS trading price proportionally; this can help address minimum listing price concerns on Nasdaq. Investors should note the split does not change ownership percentage or the ordinary shares themselves, but it will change the ADS denominators and reported per-ADS price. The company’s filing and press release are the official sources for timing and mechanics; investors should watch for confirmations from the transfer agent and any Nasdaq-related updates.